Scientists to spy on cancer cells during treatment to predict who will respond
NCT ID NCT07597642
First seen May 20, 2026 · Last updated May 23, 2026 · Updated 2 times
Summary
This study looks at tumor samples from 55 women with early-stage breast cancer (triple-negative or high-risk luminal) before, during, and after standard chemo-immunotherapy. Using single-cell RNA sequencing and imaging, researchers aim to identify early signs of treatment response or resistance. The goal is to help doctors personalize therapy and avoid ineffective treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS Ospedale San Raffaele
Milan, Lombardy, 20132, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.